Uncategorized

Recent scientific studies underscore the potential of psilocin to drive transformative neuroprotective effects by promoting neuroplasticity, reducing inflammation, and modulating microglial function, These findings open avenues for research into ALS and other neurodegenerative diseases, where overlapping mechanisms like oxidative stress and neuronal damage are central to disease progression. At Haim Pharma, we’re leveraging these insights to develop stable, disease-specific psilocin formulations that aim to redefine treatment strategies for neurodegenerative conditions. Note: This post is for informational purposes only and does not constitute medical advice.

The recent success of Qalsody (tofersen), a treatment targeting the SOD1 mutation in ALS patients, represents a significant leap forward in the fight against this devastating disease. By directly reducing the toxic buildup of SOD1 protein, Qalsody slows the progression of ALS in patients with this specific genetic mutation, improving their survival and quality of life.This progress is a game-changer for ALS research. It demonstrates the power of precision medicine to address specific genetic mutations, offering a glimpse of what’s possible for other forms of ALS. Treatments like Qalsody pave the way for exploring therapies that target different genetic and…

A groundbreaking study published in Frontiers in Neuroscience showcases the additive neuroprotective effects of a combination of tauroursodeoxycholic acid (TUDCA), coenzyme Q10 (CoQ10), and creatine in in-vitro models of Parkinson’s disease.This research demonstrates:Improved neural network density in dopaminergic neurons.Significant reduction in pro-inflammatory cytokines, particularly TNF-α and IL-6.Enhanced mitochondrial function and oxidative stress mitigation.💡 Why This Matters:The multi-target approach could serve as a model for tackling neurodegenerative diseases like ALS.It paves the way for future preclinical and clinical trials to improve patient outcomes.At Haim Pharma, we are inspired by such advancements. It aligns with our mission to innovate therapies for neurodegenerative…

HPG Adheres to national and international data protection policies. Data Protection

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive disease with no known cure. It is a neurodegenerative disease, where inflammation and oxidative stress result in the death of neurons. The current treatments do not cure the disease, they only provide a moderate improvement in the symptoms.Cannabinoids and terpenes have repeatedly demonstrated their anti-oxidative, anti-inflammatory, and neuroprotective properties. Based on in silico studies and published scientific research, we are creating a combination of non-psychoactive cannabinoids. This combination should* provide substantial relief from the ALS symptoms while slowing disease progression.This cannabinoid formulation will provide a more effective solution to the current cannabinoid-based…